The purpose of this health technology assessment (HTA) is to conduct a systematic assessment of the clinical effectiveness, safety, cost-effectiveness, and perspectives and experiences of pregnant persons, partners, and health care providers regarding the screening of pregnant persons for Chlamydia trachomatis (CT) and Neisseria gonorrhoeae (GC) during pregnancy.
Copyright © 2018 Canadian Agency for Drugs and Technologies in Health.